Natural Products

This 6-week double-blinded trial examines whether individuals in the early stages of psychosis (EP) respond to 1000 mg of endocannabinoids (CBD) with the aim of improving positive, negative, and cognitive symptoms of psychosis. Researchers are exploring the possibility that CBD might reduce anxiety, and perhaps normalize biological stress response. Symptoms, eating behaviors, metabolic parameters, cannabinoid, and biomarkers of inflammation and cortisol are measured at baseline, 3 weeks and end of study in a population with a diagnosis of first episode psychosis who are stabilized on antipsychotic medication.

A randomized, double-blinded, placebo-controlled clinical trial to evaluate the safety of FoTv (a combination of two polypore mushrooms, Fomitopsis officinalis, and Trametes versicolor) in an adult population at the time of COVID-19 vaccination. Researchers examined the effect of FoTv vs. placebo for use as an adjunct to vaccination for COVID-19. Vaccine-related side effects following COVID-19 vaccination were examined in both study groups.

A multi-centered, randomized, double-blinded, placebo-controlled clinical trial to evaluate the safety of FoTv (a combination of two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor) for COVID-positive outpatients with mild-to-moderate symptoms. Researchers used changes in COVID-19 viral load, blood markers, and a 14-day symptom diary to examine the safety, feasibility, and preliminary effects of the study product versus placebo. 

This study is in development, and recruitment has not yet begun. Once approved, additional information about study goals, eligibility, and participation requirements will be shared here. In the meantime, you may contact the study team using the email address on this page for more information.